Researchers at the Kennedy Krieger Institute, with colleagues from Johns Hopkins University, have identified an important molecular mechanism that offers significant promise for understanding and developing novel treatment for drug-resistant seizures in newborns. Newborns with drug-resistant seizures often develop childhood epilepsy and cognitive disabilities. The findings were published online this week in the journal Science Signaling. The study was led by Shilpa Kadam, Ph.D., a research scientist at Kennedy Krieger’s Hugo W. Moser Research Institute, who is also director of the mouse in-vivo electrophysiology laboratory at Kennedy Krieger.
In the paper, Targeting ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures and mitigates epileptogenesis in a mouse model, Dr. Kadam and colleagues from Kennedy Krieger and Johns Hopkins University School of Medicine showed that increasing the activity of an ion transporter in nerve cells, namely KCC2, by CLP290, a novel KCC2-selective activator, reduced seizures in mice.
Neonatal seizures typically occur within first two days after birth and in some cases as the result of impaired blood flow during a complicated birth. Babies receive phenobarbital or other common medications for seizures, but for about 50 percent of newborns seizures remain intractable. At this time, there is no FDA-approved medication to effectively prevent these treatment-resistant seizures.
“These treatment-resistant seizures come on very severely, and can sometimes be lethal. Those children that survive often develop epilepsy,” said Dr. Shilpa Kadam, “We needed out-of-the-box thinking to tackle this problem and this is our approach at Kennedy Krieger. This kind of work is a fundamental part of our mission.”
According to the study authors, their findings are the first to validate the strategy of using KCC2 as a potential drug target for treatment-resistant seizures. The findings provide important insights for future drug development. However, more work is needed to determine how best to translate these preclinical findings into human populations.
“We hope that a simple add-on intervention could effectively change the trajectory of a child’s life and may prevent the onset of lifelong epilepsy. We will be continuing to study these results and their potential application to improve child health,” Kadam said.
Recognizing the importance of the work, Kennedy Krieger’s President and Chief Executive Officer, Dr. Brad Schlaggar, noted “Dr. Kadam and her colleagues have made a valuable contribution to begin tackling the long-recognized problem of drug-resistant seizures in newborns.”
The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the U.S. National Institutes of Health (NIH).
About Kennedy Krieger Institute:
Kennedy Krieger Institute, an internationally known nonprofit organization located in the greater Baltimore-Washington, D.C., region, transforms the lives of more than 25,000 individuals a year through inpatient and outpatient medical, behavioral health and wellness therapies; home and community services; school-based programs; training and education for professionals; and advocacy. Kennedy Krieger provides a wide range of services for children, adolescents and adults with diseases, disorders and injuries that impact the nervous system, ranging from mild to severe. The Institute is home to a team of investigators who contribute to the understanding of how disorders develop, while at the same time pioneering new interventions and methods of early diagnosis, prevention and treatment. Visit KennedyKrieger.org for more information about Kennedy Krieger.
Targeting ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures and mitigates epileptogenesis in a mouse model
Article Publication Date